Q2 2025 · 13F-HR
Enavate Sciences GP, LLCholdings as filed
Filed 2025-08-14 · accession 0001415889-25-021852
$176.5M
Reported value
6
Positions
2025-06-30
Period end
The Brief · Enavate Sciences GP, LLC · Q2 2025
AI · grounded in 13F
Enavate Sciences GP, LLC established a new position in IMNM with an investment of $44.3M. The fund also opened new stakes in SION for $43M and ZBIO for $36.4M. Additional new positions include UPB, CMPX, and CAMP, bringing the total assets under management to $176.5M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 45257U108 | IMNM | IMMUNOME INC | $44.3M | 25.1% | 4,768,583 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $43.0M | 24.4% | 2,478,030 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $36.4M | 20.6% | 3,761,359 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $27.0M | 15.3% | 2,459,703 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $20.2M | 11.5% | 7,788,150 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $5.5M | 3.11% | 3,785,802 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.